Potent inhibition of recombinant human cytochrome P-450 1A1 by pentamethoxystilbene

Journal of Toxicology and Environmental Health - Part A

Volumn 67, Issue 23-24, 2004, Pages 1987-2000

  Lee, Sang Kwang ^a   Kim, Yongmo ^a   Mie, Young Kim ^a   Chun, Young Jin ^a   Kim, Sanghee ^b  

^a Chung Ang University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3,5,3',4',5' PENTAMETHOXYSTILBENE; ACETYLCYSTEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; DITHIOTHREITOL; ETHOXYRESORUFIN DEETHYLASE; GLUTATHIONE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

BACTERIAL MEMBRANE; CELL STRAIN HEPG2; CONFERENCE PAPER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; ESCHERICHIA COLI; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARCINOMA, HEPATOCELLULAR; CELL MEMBRANE; CYTOCHROME P-450 CYP1A1; ENZYME INHIBITORS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; HUMANS; LIVER NEOPLASMS; MICROSOMES, LIVER; STILBENES; TUMOR CELLS, CULTURED;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 8444236690     PISSN: 15287394     EISSN: None     Source Type: Journal    
DOI: 10.1080/15287390490514642     Document Type: Conference Paper

References (32)

1. Burke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., and Mayer, R. T. 1985. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem. Phamacol. 34:3337-3345.
2. Cai, Y., Baer-Dubowska, W., Ashwood-Smith, M. J., Ceska, O., Tachibana, S., and DiGiovanni, J. 1996. Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem. Res. Toxicol. 9:729-736.
3. Chan, W. K., and Delucchi, A. B. 2000. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67:3103-3112.
4. Chun, Y. J., and Kim, S. 2003. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents. Med. Res. Rev. 23:657-668.
5. Chun, Y. J., Kim, M. Y., and Guengerich, F. P. 1999. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun. 262:20-24.
6. Chun, Y. J., Kim, S., Kim, D., Lee, S. K., and Guengerich, F. P. 2001a. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61:8164-8170.
7. Chun, Y. J., Ryu, S. Y., Jeong, T. C., and Kim, M. Y. 2001b. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab. Dispos. 29:389-393.
8. Ciolino, H. P., and Yeh, G. C. 1999. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol. Pharmacol. 56:760-767.
9. Ciolino, H. P., Daschner, P. J., and Yeh, G. C. 1998. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 58:5707-5712.
10. Denison, M. S., Fisher, J. H., and Whitlock, J. P. 1989. Protein-DNA interactions at recognition sites for the dioxin-Ah receptor complex. J. Biol. Chem. 264:16478-16482.
11. Dolwick, K. M., Swanson, H. I., and Bradfield, C. A. 1993. In vitro analysis of Ah receptor domains involved in ligand-activated DNA recognition. Prac. Natl. Acad. Sci. USA 90:8566-8570.
12. Fujino, T., Park, S. S., West, D., and Gelboin, H. V. 1982. Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies. Proc. Natl. Acad. Sci. USA 79:3682-3686.
13. Guengerich, F. P. 1994. Analysis and characterization of enzymes. In Principles and methods of toxicology, ed. A. W. Hayes, pp. 1259-1313. New York: Raven Press.
14. Guengerich, F. P., Shimada, T., Bondon, A., and Macdonald, T. L. 1991. Cytochrome P-450 oxidations and the generation of biologically reactive intermediates. Adv. Exp. Med. Biol. 283:1-11.
15. Guengerich, F. P., Martin, M. V., Guo, Z., and Chun, Y. J. 1996. Purification of functional recombinant P450s from bacteria. Methods Enzymol. 272:35-44.
16. Henderson, M. C., Miranda, C. L., Stevens, J. F., Deinzer, M. L., and Buhler, D. R. 2000. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica 30:235-251.
17. Kim, S., Ko, H., Park, J. E., Jung, S., Lee, S. K., and Chun, Y. J. 2002. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J. Med. Chem. 45:160-164.
18. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
19. Lee, J. E., and Safe, S. 2001. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem. Pharmacol. 62:1113-1124.
20. Li, W., Harper, P. A., Tang, B. K., and Okey, A. B. 1998. Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem. Pharmacol. 56:599-612.
21. Matsuda, H., Tomohiro, N., Hiraba, K., Harimu, S., Ko, S., Matsuo, K., Yoshikawa, M., and Kubo, M. 2001. Study on anti-Oketsu activity of rhubarb II. Anti-allergic effects of stilbene components from Rhei undulati rhizoma (dried rhizome of Rheum undulatum cultivated in Korea). Biol. Pharm. Bull. 24:264-267.
22. Nebert, D. W. 1989. The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects. Crit. Rev. Toxicol. 20:153-174.
23. Omura, T., and Sato, R. 1964. The carbon-monoxide binding pigment of liver microsomes. J. Biol. Chem. 239:2370-2378.
24. Parikh, A., Gillam, E. M. J., and Guengerich, F. P. 1997. Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat. Biotechnol. 15:784-788.
25. Reyes, H., Reisz-Porezasz, S., and Hankinson, O. 1992. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 256:1193-1195.
26. Rowlands, J. C., and Gustafsson, J. A. 1997. Aryl hydrocarbon receptor-mediated signal transduction. Crit. Rev. Toxicol. 27:109-134.
27. Shimada, T., Yamazaki, H., Foroozesh, M., Hopkins, N. E., Alworth, W. L., and Guengerich, F. P. 1998. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 11:1048-1056.
28. Swanson, H. I., and Bradfield, C. A. 1993. The AH-receptor: genetics, structure and function. Pharmacogenetics 3:213-230.
29. Wedlund, P. J., Kimura, S., Gonzalez, F. J., and Nebert, D. W. 1994. 1462V mutation in the human CYP1A1 gene: Lack of correlation with either the Msp I 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent. Phamacogenetics 4:21-26.
30. Whitlock, J. P. 1999. Induction of cytochrome P450 1A1. Annu. Rev. Phamacol. Toxicol. 39:103-125.
31. Yang, C. S., Smith, T. J., and Hong, J. Y. 1994. Cytochrome P450 enzymes as targets for chemoprevention against chemical carcinogenesis and toxicity opportunities and limitations. Cancer Res. 54:1982s-1986s.
32. Zhai, S., Dai, R., Friedman, F. K., and Vestal, R. E. 1998. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos. 26:989-992.